NPR2 and achondroplasia: These accumulating results, together with evidence that a PPP-family phosphatase mediates the FGF-induced dephosphorylation and inactivation of NPR2 (26, 27), suggest that a PPP-family phosphatase inhibitor could enhance bone growth in ACH patients if applied together with a CNP analog.